Sol Barer - InspireMD Independent Chairman of the Board
| NSPR Stock | USD 3.00 0.02 0.67% |
Chairman
Dr. Sol J. Barer, Ph.D., is Independent Chairman of the Board of InspireMD, Inc. Sol J. Barer, Ph.D., has served as a director since July 11, 2011 and has served as our chairman since November 16, 2011. Dr. Barer has 25 years of experience with publicly traded biotechnology companies. In 1980, when Dr. Barer was with Celanese Research Company, he formed the biotechnology group that was subsequently spun out to form Celgene Corporationrationration. Dr. Barer spent 18 years leading Celgene Corporation as president, chief operating officer and chief executive officer, culminating with his tenure as Celgene Corporationrationrations executive chairman and chairman beginning in May 2006 until his retirement in June 2011. Dr. Barer is also a director of Cerecor, Inc., Edge Therapeutics, Inc., Medgenics, Inc., ContraFect Corporationrationration, Amicus Therapeutics, Inc. and Aegerion Pharmaceuticals, Inc. and serves as a senior advisor to a number of other biotechnology companies since 2011.
| Age | 77 |
| Tenure | 13 years |
| Professional Marks | Ph.D |
| Address | 4 Menorat Hamaor Street, Tel Aviv, Israel, 6744832 |
| Phone | 972 3 6917691 |
| Web | https://www.inspiremd.com |
Sol Barer Latest Insider Activity
Tracking and analyzing the buying and selling activities of Sol Barer against InspireMD stock is an integral part of due diligence when investing in InspireMD. Sol Barer insider activity provides valuable insight into whether InspireMD is net buyers or sellers over its current business cycle. Note, InspireMD insiders must abide by specific rules, including filing SEC forms every time they buy or sell InspireMD'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Sol Barer over six months ago Disposition of 37598 shares by Sol Barer of Teva Pharma subject to Rule 16b-3 |
InspireMD Management Efficiency
The company has return on total asset (ROA) of (0.3724) % which means that it has lost $0.3724 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6675) %, meaning that it created substantial loss on money invested by shareholders. InspireMD's management efficiency ratios could be used to measure how well InspireMD manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/22/2024, Return On Tangible Assets is likely to drop to -0.44. In addition to that, Return On Capital Employed is likely to drop to -0.53. At this time, InspireMD's Total Assets are relatively stable compared to the past year. As of 12/22/2024, Total Current Assets is likely to grow to about 46.4 M, while Non Currrent Assets Other are likely to drop slightly above 654.2 K.Similar Executives
| Found 3 records | CHAIRMAN Age | ||
| Dan Gladney | ReShape Lifesciences | 71 | |
| Richard Ferrari | Tenon Medical | 70 | |
| Scott JD | IRIDEX | 59 | |
Management Performance
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.37 |
InspireMD Leadership Team
Elected by the shareholders, the InspireMD's board of directors comprises two types of representatives: InspireMD inside directors who are chosen from within the company, and outside directors, selected externally and held independent of InspireMD. The board's role is to monitor InspireMD's management team and ensure that shareholders' interests are well served. InspireMD's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, InspireMD's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shane Gleason, Chief Officer | ||
| Roei Samuri, VP Operations | ||
| DVM MD, Executive Affairs | ||
| Craig Shore, CFO, Chief Admin. Officer, Secretary and Treasurer | ||
| Andrea Tommasoli, Chief Officer | ||
| Amir Kohen, Vice Resources | ||
| Marvin Slosman, CEO President | ||
| Pete Ligotti, Executive America | ||
| Sol Barer, Independent Chairman of the Board |
InspireMD Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is InspireMD a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.37 | ||||
| Operating Margin | (4.68) % | ||||
| Current Valuation | 39.86 M | ||||
| Shares Outstanding | 26.08 M | ||||
| Shares Owned By Insiders | 16.99 % | ||||
| Shares Owned By Institutions | 40.84 % | ||||
| Number Of Shares Shorted | 175.04 K | ||||
| Price To Earning | (0.16) X | ||||
| Price To Book | 1.91 X |
Pair Trading with InspireMD
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if InspireMD position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in InspireMD will appreciate offsetting losses from the drop in the long position's value.Moving together with InspireMD Stock
Moving against InspireMD Stock
| 0.63 | ENSG | Ensign Group | PairCorr |
| 0.62 | DRIO | DarioHealth Corp | PairCorr |
| 0.6 | EDAP | EDAP TMS SA | PairCorr |
| 0.49 | VTAK | Catheter Precision | PairCorr |
| 0.49 | EKSO | Ekso Bionics Holdings | PairCorr |
The ability to find closely correlated positions to InspireMD could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace InspireMD when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back InspireMD - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling InspireMD to buy it.
The correlation of InspireMD is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as InspireMD moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if InspireMD moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for InspireMD can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for InspireMD Stock Analysis
When running InspireMD's price analysis, check to measure InspireMD's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InspireMD is operating at the current time. Most of InspireMD's value examination focuses on studying past and present price action to predict the probability of InspireMD's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InspireMD's price. Additionally, you may evaluate how the addition of InspireMD to your portfolios can decrease your overall portfolio volatility.